Early diagnosis of human cytomegalovirus (HCMV) infection and the introduction of preemptive antiviral therapy have reduced HCMV-related mortality after allogeneic stem cell transplantation. A critical goal remains stratifying risk profiles and minimizing potential harm owing to antiviral overtreatment. We compared the commercially available standardized COBAS Amplicor CMV Monitor (CACM) to an in-house PCR assay, for the monitoring of HCMV infection. Seventy-two patients were surveyed by an in-house PCR of whole blood, quantitative viral load assessment by CACM and virus culture assays in a prospective and a retrospective study. A high concordance between CACM and PCR was documented. The viral load at onset correlated with the peak viral load (Spearman rank correlation R ¼ 0.634, P ¼ 0.0004). In patients developing HCMV disease, both viral loads were in trend higher (P ¼ 0.823, respectively P ¼ 0.053), and the viremic episodes longer (P ¼ 0.015), as compared to asymptomatically HCMV-infected patients. The serological pre-transplant status was the major risk factor for the development of HCMV disease, showing highest risk for seropositive patients receiving a seronegative graft, whereas donor type (related or unrelated) and graft type (bone marrow or peripheral blood mobilized stem cells) did not have an influence. HCMV infection proved to be a risk factor for the development of non-viral opportunistic infections (P ¼ 0.002).
Introduction
Human cytomegalovirus (HCMV) infection remains a major cause of morbidity and mortality in patients after allogeneic stem cell transplantation (SCT). [1] [2] [3] [4] Before the introduction of prophylactic and preemptive antiviral therapy, up to 50% of allogeneic bone marrow transplant recipients with active HCMV infection developed HCMV disease. Clinical presentation of HCMV organ disease includes pneumonitis, gastroenteritis or, more rarely, hepatitis, retinitis and neurological disorders. Despite combined antiviral and immunoglobulin prophylaxis, the case fatality rate in these patients remains very high (for HCMV pneumonitis between 30 and 70%). 5 Ganciclovir prophylaxis of HCMV-seropositive patients during the first 100 days after transplantation significantly decreased the incidence of HCMV disease, but could not improve survival among SCT recipients owing to ganciclovirassociated myelosuppression and subsequent infectious complications. 6 The commercially available CACM has been developed for the determination of the HCMV-DNA load in plasma samples. [7] [8] [9] This semi-automated PCR amplification system provides clinical laboratories with a standardized assay for detection and quantification of HCMV in plasma, featuring high sensitivity and specificity and allowing result comparison between different laboratories and transplant centers. In this study, we compared the CACM to an in-house PCR assay for its potential for early diagnosis and monitoring of HCMV infection in allogeneic SCT patients, and analyzed the clinical relevance of viral load measurement in this setting.
Patients and methods
A quality control study comparing the performance of CACM to our in-house PCR was conducted. Forty-one patients were studied prospectively between January 1999 and April 2000 after allogeneic SCT. Patients were assigned to weekly monitoring for signs of HCMV infection by inhouse PCR from whole blood, CACM and virus culture assays until day 100, and in case of persistence of immunosuppression, every other week until day 180. A total of 490 samples from 41 patients were analyzed by CACM and in-house PCR in this prospective study. In addition, we performed a retrospective analysis of 221 samples from 21 SCT patients with a high viral load, or HCMV disease, treated in our hospital between November 1998 and April 2000. A third group included 10 patients (233 samples), observed in part prospectively and retrospectively. Patients' characteristics at time of transplant are shown in Table 1 .
Preparative regimens were assigned according to clinical treatment protocols: The patients underwent either a regimen including 12 Gy of accelerated fractionated total body irradiation (2 Gy twice a day for 3 consecutive days, lung shielding 10 Gy) followed by 2 days of cyclophosphamide 2 Â 60 mg/kg body weight/day or a combination chemotherapy regimen containing busulfan 4 Â 1 mg/ kg body weight/day for 4 days and cyclophosphamide in the specified dosage. Patients not eligible for high-dose therapy underwent a non-myeloablative preparation regimen consisting of fludarabine 30 mg/m 2 for 5 days, cyclophosphamide 20 mg/kg for 2 days and antithymocyte globulin at a dose of 10 mg/kg for 3 days. Donor marrow or peripheral blood stem cells were infused on day 0. Graft-versus-host prophylaxis consisted of cyclosporin7 prednisolone7antithymocyte globulin. Oral acyclovir (4 Â 400 mg/day) was administered to all patients for prophylaxis of herpes simplex infection beginning with the preparative treatment and until day þ 100. All HCMVseropositive patients and/or those receiving a transplant from an HCMV-seropositive donor received blood products unscreened for HCMV.
Definitions of HCMV infection and disease
All patients with one positive in-house PCR test result were considered to be actively HCMV infected. HCMV disease was diagnosed according to the criteria defined by the Fourth International Cytomegalovirus Workshop in Paris 1993, as follows: HCMV pneumonia: dyspnea, interstitial infiltrates on chest radiograph, positive HCMV culture of bronchial washings; HCMV enteritis: gastrointestinal symptoms, demonstration of HCMV by histology or immunohistology; HCMV retinitis: typical morphological changes. 10 Therapy for HCMV infection and disease PCR-based preemptive therapy with ganciclovir (dosage 2 Â 5 mg/kg body weight/day) or foscarnet (dosage 2x60 mg/kg body weight/day) was initiated after the second consecutive positive in-house PCR result was documented. 11 In cases where HCMV disease was diagnosed, patients received combination therapy with ganciclovir and hyperimmunoglobulin as reported before.
1-4 Antiviral therapy was stopped after 14 days if clearance of the virus could be documented by PCR. If the PCR remained positive after 14 days of antiviral therapy, maintenance therapy with ganciclovir 6 mg/kg/day 5 Â weekly or foscarnet 90 mg/kg/day 5 Â weekly was administered. In patients refractory to antiviral therapy and in patients with a very high viral load and symptomatic HCMV disease, combination therapy with ganciclovir and foscarnet as well as cidofovir was applied. CACM results were not considered for clinical assessment.
Quantitative assessment of the viral load in the blood by COBAS Amplicor HCMV Monitor Test (Roche Diagnostics, Mannheim, Germany) Nucleic acid was extracted from 0.2 ml EDTA-anticoagulated plasma according to the manufacturer's protocol. Specific primers amplified a 365 bp region of the HCMV DNA polymerase gene. The viral load was assessed by using an external standard and colorimetric amplicon detection. The lower detection limit of the assay was 400 copies/ml plasma. Linearity of the assay was achieved between 400 and 1 Â 10 5 copies/ml plasma.
Polymerase chain reaction DNA extraction of 5 ml EDTA-anticoagulated blood was performed as previously reported 14 using the Qiagen Blood Kit (Qiagen, Hilden, Germany). A 147-bp DNA fragment was amplified between positions 1767 and 1913 of the fourth exon of the immediate-early gene of the HCMV strain AD169 using 100 ng human DNA, PCR reaction mix and specific primers as described before. 12 In all assays, amplification of 0.1, 1, 10 and 100 fg of the cloned HCMV-DNA fragment pCM5018 was included. Amplicons were detected using the slot blot hybridization technique with a digoxigenin-labeled oligonucleotide specific for HCMV and alkaline phosphatase-labeled anti-digoxigenin antibodies (Roche, Mannheim, Germany). The intensity of the signals of the titration curve was compared with the signal from each clinical sample and a semi-quantitative assessment was performed as previously described. 13 The detection limit of the assay was 0.1-1 fg HCMV-DNA, with a lower detection limit corresponding to 30 virus copies. PCR results were available within 24 h.
Virus culture
Human foreskin fibroblasts grown in glass tubes were inoculated for 45 min at 371C with 0.2 ml of a leukocyte suspension (1-2 Â 10 6 cells) prepared by dextran sedimentation. Human foreskin fibroblasts were maintained in culture in minimum essential medium at 371C. HCMV was identified by detection of its characteristic cytopathic effects on human foreskin fibroblasts. In a separate identically inoculated culture, HCMV-specific immediate-early antigens were detected 48 h after inoculation by an indirect peroxidase technique. Cultures were fixed with cold methanol for 10 min. Monoclonal antibody E13 (Biosoft, Paris, France; dilution 1:750), which is directed against HCMV immediate-early antigen, was added for 60 min at 371C. Subsequent incubation with peroxidase-conjugated rabbit anti-mouse Ig antibody (Dako, Hamburg, Germany; dilution: 1:750) and with the chromogen aminoethylcarbazol (Sigma, St Louis, MO, USA) yielded brown nuclear staining of infected cells. Cultures were read in a Leitz Fluovert microscope at a 63-fold magnification.
Statistical considerations
Patient data were documented and monitored by the Department of Haematology and Oncology, Tu¨bingen and transferred to the Institute for Medical Information Processing, which conducted the statistical analyses. All statistical analyses in this study were carried out for descriptive purposes. Continuous variables are expressed as mean value7standard deviation or as median and ranges depending on their distribution. Discrete variables are expressed as counts and percentages. Results of statistical tests are presented with two-tailed P-values (unadjusted for multiple comparisons). Computations were performed using SAS-PC for Windows (Version 9.1; SAS Institute Inc., Cary, NC, USA). 14 Forty-nine out of 72 patients studied were HCMV positive according to the PCR result from whole blood and were considered as having a viremic episode. In 40 of these 49 patients (81.6%), both assays gave a positive result, whereas nine patients tested positive by the in-house PCR were CACM negative (18.3%). None of these nine patients developed HCMV disease. Thirty-four patients had two consecutively positive HCMV-PCR results within 14 days and were given antiviral therapy.
Results

CACM for diagnosis of HCMV infection
In two patients, routine screening by in-house PCR failed to detect HCMV infection owing to a mutation in the primer binding site. In the first patient, CACM showed positivity at day 69; 7 days later, HCMV pneumonia was diagnosed in a bronchoalveolar lavage specimen. In spite of antiviral treatment, the patient died of respiratory failure after another 22 days. The second patient was diagnosed with pneumonia on day 34 post transplantation. He recovered and was found to be CACM negative after 30 days of antiviral treatment, but eventually died during the course of a second HCMV reactivation and pneumonia on day 169 post transplantation.
Viral load kinetics
Monitoring of the viral kinetics renders possible screening for HCMV disease. Therefore, duration, viral load at onset CACM in HCMV monitoring after allogeneic SCT C Lengerke et al and peak of the first viremic episode were analyzed as prognostic factors for HCMV disease.
We calculated a minimum and maximum duration of the first viremic episodes of all patients. Mean of the minimal duration (from day of first to day of last positive PCR) was 25.4 days (median 15.5 days, range 1-143 days). Mean of the maximal duration (from day of last negative PCR before episode to day of first negative PCR after episode) was 41.1 days (median 30 days, range 6-148 days). Estimation of maximum duration of the first viremic episode was made to document possible bias made by the monitoring method. For the following analyses only dates for the minimum calculation were used. Patients with asymptomatic HCMV infection experienced shorter first viremic episodes than did patients eventually developing HCMV disease (median 12.5 and 17 days respectively, P ¼ 0.069). The same trend could be determined by summarizing all viremic episodes: median 22 days for asymptomatically infected patients, and 44 days for patients developing HCMV disease (P ¼ 0.015).
Data for viral load at onset of viremia were evaluated for 27 patients with viremic episodes for their first episode within 150 days post transplantation. Median of the viral load at onset for these patients was 5546 (range 318-43 800) and median of the peak viral load 14 600 (range 318-555 000; n ¼ 33). The onset viral load correlated with peak HCMV load (Spearman rank correlation R ¼ 0.634, P ¼ 0.0004). Viral load at onset as well as peak viral load was higher in patients experiencing HCMV disease, although the difference was not statistically significant (median: 2910 compared to 1780, P ¼ 0.823, respectively 4955 vs 33 500, P ¼ 0.053) ( Table 2 ).
HCMV therapy monitoring by CACM
To evaluate CACM for HCMV therapy monitoring, we studied 18 therapy courses in patients who were monitored with documented viral load at the onset of the viremic episode and no more than 14 days after the beginning of treatment. Viral load decreased in five of the patients, 11 patients had an increasing viral load, whereas two patients dropped out owing to insufficient monitoring. These results were constantly observed for a longer period of 28 days after the beginning of therapy. Quantitative course of the viral load under therapy was not predictive for the development of HCMV disease.
Evaluation of other parameters as risk factors for HCMV disease development
Symptomatic HCMV disease within 150 days post transplantation was documented in 14 of 72 patients studied. Ten patients experienced interstitial pneumonia, two patients colitis and two other patients interstitial pneumonia combined with retinitis or, respectively, colitis. Additionally, one patient, who experienced an extended viremic episode over 118 days and was followed up until day 139, was eventually diagnosed with late HCMV retinitis on day 173 post transplantation. Patients experiencing a viremic episode, without developing HCMV disease, were considered asymptomatically infected. Patient characteristics are summarized in Table 3 .
Although there was no difference in the incidence of HCMV disease correlating with donor type (related or unrelated) or graft type source (bone marrow or mobilized stem cells from peripheral blood stem), the donor/recipient HCMV serological status proved to be a predictive factor. HCMV disease occurred, on our study, only in seropositive patients, with a higher frequency in those receiving seronegative grafts. Data are shown in Table 3 .
HCMV viremia enhances the risk of developing non-viral opportunistic infections
HCMV infection significantly increased the risk of developing non-viral, mostly fungal, opportunistic infections, after allogeneic SCT (Mantel-Haenszel test: P ¼ 0.028 respectively P ¼ 0.002). Interestingly, the relative risk was not higher for patients with HCMV disease (relative risk 2.86, 95% confidence interval (CI) ¼ 1.55-5.32), when compared to asymptomatic HCMV-infected patients (relative risk 2.97, 95% CI ¼ 0.98-9.04) ( Table 4) .
Discussion
Appropriate management of HCMV in allogeneic SCT patients depends on sensitive, rapid and reliable early sensitive detection methods and a low cutoff value to trigger preemptive antiviral therapy are crucial in these patients. Virus isolation and shell vial culture have been accepted as standards for HCMV detection. Yet, conventional cell culture and shell vial assay may become positive only when HCMV disease is already present. 11, 17 More recently, pp65-antigenemia assays and PCR methods have been established for HCMV monitoring of patients at risk. 14, 18, 19 Preemptive antiviral therapy based on pp65-antigenemia and HCMV-DNA PCR assays has been shown to significantly reduce both HCMV disease incidence and HCMV-associated mortality following allogeneic SCT in the early post transplant period, 11, 12, [20] [21] [22] [23] and has become a standard of care in many transplant centers. Preemptive ganciclovir therapy based on HCMV-pp65-antigenemia has resulted in an HCMV disease rate of approximately 14%. 24 The use of preemptive therapy based on any positive pp65 assay combined with a longer course of ganciclovir (until day 100) 20 or based on two consecutive positive PCR tests of whole blood 11 successfully reduced the rate of early HCMV disease to 3.8 and 5.4%, respectively.
In this study, CACM in plasma showed very good sensitivity and specificity for detection of early HCMV infection, comparable with the in-house PCR on whole blood. Both the prospective and the retrospective sample analyses revealed a high concordance between the two methods (89.2%, McNemar test: Po0.0001, respectively 91.9%, McNemar test: P ¼ 0.096). There was no significant difference in the time point of HCMV infection diagnosis (median, 35 days post transplantation; P ¼ 0.65). All patients with HCMV disease were correctly identified by CACM. Nine patients, all analyzed prospectively, displayed a positive in-house PCR result, while being negative by CACM. In six of these patients, the result was shortly followed by a negative PCR result in the next sample, so that preemptive therapy had not yet been initiated. Just one out of these nine patients showed two consecutive positive PCR results, and was started on antiviral therapy. In this patient, HCMV disease could have theoretically developed in spite of a negative result by CACM, yet it is also possible that without preemptive therapy, the viral loads would have reached levels detectable by CACM also in time for an appropriate therapy start. 31 also showed high concurrence of results for early HCMV detection.
However, beyond early detection of HCMV infection, appropriate management in this clinical setting also involves avoiding potential harm owing to antiviral overtreatment. Ganciclovir therapy is associated with significant myelotoxicity and can delay HCMV-specific T-cell reconstitution; higher rates of invasive fungal infections and an increased incidence of late HCMV disease have been reported after prolonged ganciclovir therapy. [6] [7] [8] 24 Antiviral therapy for more than 4 weeks before day 100, and acute graft-versus-host disease and corticosteroid treatment have proved to be important risk factors for late HCMV disease in a cohort of patients receiving PCR-based antiviral therapy. 8 While being comparably efficient and significantly less myelotoxic, 32 foscarnet proved poorly tolerated in HCMV prophylaxis of SCT patients: 81% experienced adverse effects like gastrointestinal complaints, headache or urethritis, leading to dose reductions in 38% of cases and 23.8% to drop out of the study. 33 Assessment of viral load kinetics may provide a tool for stratifying risk profiles for HCMV disease and help reduce the considerable rate of antiviral overtreatment. Although a correlation between peak viral load and HCMV disease development was noticed by several other groups in patients after solid organ transplantation and HIV patients, 28, [34] [35] [36] [37] [38] [39] discordant results have been reported in SCT patients. 15, 16, 22, 31, 40 For abbreviations, see Table 1 footnote. Emery et al. 40 found both the initial viral load and the increased rate in viral load to be predictive for HCMV disease development in patients after kidney, liver and allogeneic SCT. Our study could not confirm these results. Although we observed a trend for higher initial viral load, higher peak viral load and longer duration of viremia in patients developing HCMV disease, the difference was not significant. The positive correlation between initial and peak viral load indicates that low initial viral loads, maybe as found at earlier time points of HCMV viremia diagnosis, are better controlled by antiviral therapy and lead to lower peak viral loads. Nevertheless, patients experiencing HCMV infections progressing to HCMV disease did not experience significantly higher viral loads. Hence, our data support the hypothesis that in allogeneic SCT patients, in contrast to patients after solid organ transplantation, HCMV disease can develop in spite of low levels of HCMV viral load. 15, 16 As there is evidence that immune reconstitution occurs earlier after peripheral blood SCT than after bone marrow transplantation, 41 we analyzed whether graft type could be a risk factor for HCMV disease development. Surprisingly, disease incidence in patients diagnosed with HCMV infection was not increased in the bone marrow transplant group, and was also not influenced by donor type (related vs unrelated). The data confirm recent findings by Junghanss et al. 42 regarding the status of the donor type, as well as the observation that a non-myeloablative conditioning regimen may delay the onset of HCMV disease but not reduce its overall 1-year incidence, when compared to myeloablative allogeneic SCT. 43 An important risk factor for the development of HCMV disease remains pre-transplant serological status. In our study, HCMV disease occurred only in seropositive patients, regardless of donor HCMV status. Interestingly, seropositive patients receiving seronegative transplants were at higher risk than their counterparts transplanted with HCMV-positive grafts. The correlation between HCMV seropositivity and HCMV disease development is consistent with other studies, 44 yet the particular donordependent risk within this population has, to our knowledge, not yet been reported.
In theory, HCMV infection exerts an immunosuppressive effect and enhances the risk for non-viral opportunistic infections. [45] [46] [47] [48] Nichols et al. 49 showed an increased risk particularly for patients during primary infection (D þ /R À ). In our study, HCMV viremia, also without subsequent HCMV disease, seems to be a risk factor for the development of non-viral opportunistic infections. Additional myelosuppression by the preemptive antiviral medication may partly account for this effect.
In conclusion, according to our experience, CACM is a reliable method for early detection of HCMV infection. As a standardized method, it allows inter-center result comparison. Assessment of viral load kinetics has proved suggestive, but not conclusive for monitoring of HCMV infection, implying differences in the allogeneic SCT setting, when compared to solid organ transplantation. The most important risk factor for the development of HCMV disease was recipient seropositivity pre-transplant, especially after transplantation of a seronegative graft.
Further studies are needed to confirm this observation and to clarify the underlying mechanisms.
